1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Canton Strategic Holdings Inc

Canton Strategic Holdings Inc

CNTN
Canton Strategic Holdings IncUS flagNASDAQ Capital Market
2.51
USD
-0.06
- -
87.96MMarket Cap
Canton Strategic Holdings Inc
CNTN
(NASDAQ Capital Market)

Recent

price

2.51

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-50.93
-80.71
-80.38
-280.76
-107.02
-9.41
-1.12
-1.12
Basic EPS, GAAP
-23.57
-36
-39.57
-217.3
-83.83
-8.41
-2.92
-1.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-69.6
-157.05
-251.72
-509.77
-283.69
-28.47
-2.27
-1.66
Book Value per Share
-54.16
-124.11
-170.65
183.69
104.86
1.01
-3.24
-0.99
Tangible Book Value per Share
- -
- -
- -
- -
- -
1
32
72
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-2
-2
-8
-9
-12
-36
-81
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1
-2
-4
6
9
1
14
42
Working Capital
1
1
1
- -
- -
- -
- -
- -
LT Debt
-2
-4
-5
6
9
1
398
470
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
37
57
Market Capitalization
11
12
236

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
8
17
43
Cash, Cash Equivalents & STI
8
17
42
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
3
1
Payables & Accruals
1
3
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
6,023.51%
30,330.8%
Free Cash Flow
- -
264.92%
759.48%
Net Income, GAAP
- -
102.12%
194.45%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2.55
-2.42
-2.45
- -
-9.41
2025
-0.99
-0.64
-0.34
- -
-1.12
2026
-0.23
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
CASI Pharmaceuticals, Inc. (CASI)
AnPac Bio-Medical Science Co., Ltd. (ANPC)
Caris Life Sciences, Inc. (CAI)
BiomX Inc. (PHGE)
Spruce Biosciences, Inc. (SPRB)
LexaGene Holdings Inc. (0V43.L)
Business
Canton Strategic Holdings Inc. engages in Canton Network-related activities and biotechnology development, combining digital-asset infrastructure initiatives with clinical-stage biotech research and development. The company focuses on leveraging Canton Coin to support blockchain-based financial market digitization, operates validator nodes to facilitate network security and governance, and pursues a diversified biotechnology pipeline led by GV104 and GV023 for specialty therapeutic indications. Canton Strategic Holdings also pursues strategic investments and partnerships to advance institutional adoption of the Canton Network, including participation in network governance through board roles and ecosystem collaborations. The company was founded in 2017 and is headquartered in Frankfurt am Main, with its primary listing and public disclosures centered in the United States and international market channels. Subsidiaries and affiliates span technology infrastructure operations tied to Canton Network services and biotechnology development platforms, positioning the firm as a multi-industry holding with a core emphasis on digital asset infrastructure, network governance, and targeted biopharmaceutical innovation. As of its latest developments, the company completes major financing rounds to expand Canton-centric digital-asset treasury activities, broadens its validator footprint to support increasing daily transaction volumes, and strengthens governance participation through board appointments and strategic alliances. The近-term strategy emphasizes accelerating network momentum, expanding capital capacity, and advancing targeted therapeutic programs, while maintaining a focus on long-term shareholder value through diversified operating assets and strategic partnerships.

Company News

APIChatGPT

  • prnewswire.com

    Canton Strategic Holdings, Inc. Announces Launch of Locking Service to Support Network Infrastructure Providers

  • prnewswire.com

    Canton Strategic Holdings, Inc. Expected to Be Included in Russell 3000® and Russell 2000®

  • prnewswire.com

    Canton Strategic Holdings, Inc. Announces Authorization of Share Repurchase Program

  • prnewswire.com

    Canton Strategic Holdings Reports First Quarter 2026 Financial and Operational Results

  • prnewswire.com

    Canton Strategic Holdings, Inc. Presents Quarterly Canton Network Ecosystem Update

  • prnewswire.com

    Canton Strategic Holdings Reports Full Year 2025 Financial and Operational Results

  • businesswire.com

    BitGo to Securely Store Digital Asset Treasury Holdings for Canton Strategic Holdings, Inc.

  • prnewswire.com

    Canton Strategic Holdings, Inc. Chairman and CEO Mark Wendland Elected to Canton Foundation Board